Bibliographic Details
| Title: |
The Effect of Renaltec on Serum Uremic Toxins in Cats with Experimentally Induced Chronic Kidney Disease. |
| Authors: |
Paschall, Rene E., Quimby, Jessica M., Lourenço, Bianca N., Summers, Stacie C., Schmiedt, Chad W. |
| Source: |
Veterinary Sciences; Aug2024, Vol. 11 Issue 8, p379, 14p |
| Subject Terms: |
CHRONIC kidney failure, KIDNEY diseases, KIDNEY physiology, TOXINS, BLOOD pressure, KIDNEYS |
| Abstract: |
Simple Summary: In cats with chronic kidney disease (CKD), harmful toxins can build up in their blood, causing health problems. Some of these toxins originate from molecules that are generated in the gut by the action of certain microbes on digested food. Renaltec is a supplement that binds to these molecules in the gut before they enter the bloodstream and are transformed into toxins by the liver. In a study with 13 cats with experimentally induced CKD, researchers tested how well Renaltec worked at reducing two specific toxins, indoxyl sulfate and p-cresol sulfate, in the blood. The cats were given Renaltec either once or twice daily for 56 days, and their toxin levels were measured at different times. The study found that Renaltec significantly lowered the levels of these toxins, with the twice-daily dosing showing better results. This suggests that Renaltec is effective at reducing harmful toxins in cats with CKD. Serum uremic toxins markedly increase in cats with chronic kidney disease (CKD) and have deleterious consequences. Renaltec is an oral adsorbent that binds uremic toxin precursors in the gut. In this prospective cohort study utilizing 13 purpose-bred cats with remnant kidney model-induced CKD (12 IRIS Stage 2, 1 IRIS Stage 3) eating a standardized renal diet, we aimed to assess the effect of Renaltec administration on serum indoxyl sulfate (IDS) and p-cresol sulfate (pCS) concentrations. Cats were sequentially treated with standard of care for 56 days, 500 mg Renaltec orally once daily for 56 days, and then three months later, 500 mg Renaltec orally twice daily for 56 days. Serum IDS and pCS concentrations were measured 28 and 56 days after the administration of Renaltec. Blood pressure and kidney function were measured before and 56 days after the administration of Renaltec. Significant decreases in serum IDS and pCS concentrations were observed for both once- and twice-daily dosing, particularly during the first 28 days of administration. More cats with BID dosing had clinically significant reductions in serum IDS and pCS concentrations than with SID dosing. Renaltec can reduce the serum concentrations of deleterious gut-derived uremic toxins in cats with CKD. [ABSTRACT FROM AUTHOR] |
|
Copyright of Veterinary Sciences is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
